News Hub | News Direct

All Industries


Article thumbnail News Release

Torque Metals starts drilling for gold at Paris

TORQUE METALS LIMITED

Torque Metals Ltd (ASX:TOR) managing director Cristian Moreno talks with Proactive’s Jonathan Jackson about drilling at the company’s Paris Gold Project in Western Australia, which aims to expand high-grade gold structures across several prospects. The 6,500-metre campaign is set to explore the Paris, Observation, HHH and Eva prospects, focusing on a 2.5 kilometres by 1 kilometre area influenced by the Boulder Lefroy System. This region exhibits potential for multiple deposits within a broader mineralised system, underpinned by parallel structures and splays. Moreno expressed confidence that this extensive drilling program will substantiate the gold endowment at Paris and help to transform it into a significant resource. Contact Details Proactive Investors Jonathan Jackson +61 413 713 744 jonathan@proactiveinvestors.com

April 05, 2024 11:05 AM Eastern Daylight Time

Video
Article thumbnail News Release

Lithium Energy agrees to spin out new graphite company with NOVONIX

LITHIUM ENERGY LIMITED

Lithium Energy Ltd (ASX:LEL) general manager of projects Graham Fyfe sits down with Proactive’s Jonathan Jackson to discuss a pivotal agreement with NOVONIX Ltd to merge Queensland graphite assets, leading to the formation of Axon Graphite Ltd. This strategic move aims to amass a high-grade graphite inventory, propelling the development of an Australian-based, vertically integrated battery anode material (BAM) business. Axon Graphite, which plans to IPO, will focus on leveraging the combined strengths of the Burke and Mt Dromedary graphite deposits, optimising operational synergies and economies of scale. Lithium Energy shareholders stand to gain from this venture, with a priority offer and retained interest in Axon, highlighting a promising trajectory for this dedicated Australian graphite enterprise. Contact Details Proactive Investors Jonathan Jackson +61 413 713 744 jonathan@proactiveinvestors.com

April 05, 2024 11:00 AM Eastern Daylight Time

Video
Article thumbnail News Release

Non-addictive options to Opioids: Exploring Pain Relief Options Before Taking Opioids

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/RjjYJwM-XFc While opioid dispensing rates in the U.S. are slowly ticking down, they remain elevated compared with rates in other countries. The U.S. makes up only 4.4% of the world’s population, but it consumes over 80% of the world’s opioids Luckily, consumers today have more options than ever before for powerful, nonaddictive pain relief as they navigate their unique positions on the overall pain spectrum, including but not limited to over-the-counter (OTC) medications, physical therapy, medication and chiropractic care. Mothers Against Prescription Drug Abuse (MAPDA) in partnership with Aleve®, a marquee pain relief product from Bayer indicated for minor pain, launched “The Painful Truth,” campaign developed to encourage consumers to explore, with their doctors, pain relief options such as OTC products before taking opioids, when appropriate. “The Painful Truth” campaign launched with a film featuring real pain sufferers who are at crossroads in their pain relief journeys and seeking guidance. The featured patients believe they are participating in a video call with a pain expert who will help them explore their options, but as the conversation progresses, our “expert” reveals that they are in fact in recovery from opioid use disorder. At this critical juncture in their care, the patients are encouraged to consider different pain relief options. A nationwide media tour was conducted on March 26th featuring Mary Bono, Co-Founder, Chair of the Board of Directors & CEO of Mother’s Against Drug Abuse (MAPDA) and Matt Robinson, A voice from “The Painful Truth” campaign and Co-Host of Till the Wheels Fall Off (TWFO) podcast. Topics that were discussed included: · What people need to know about the pain relief options available to them before taking opioids when appropriate and after discussion with their healthcare provider. · Matt’s first-person experience with opioid use disorder. · The work Mother’s Against Drug Abuse has done to address the issue. · How patients can choose and advocate for themselves as it relates to pain management. For more information, visit aleve.com/thepainfultruth. About with Mothers Against Prescription Drug Abuse (MAPDA) Founded in 2011, Mothers Against Prescription Drug Abuse is a nationally recognized 501(c)(3) nonprofit organization focused on policy advocacy, opioid use disorder (OUD) prevention education, and opioid awareness programs. For more information, visit mapda.net. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to www.bayer.com. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

April 05, 2024 10:39 AM Eastern Daylight Time

Video
Article thumbnail News Release

Bitget Lists Solana-based "Cat in a Dogs World" (MEW) in the Innovation and Meme Token Zone

Bitget

Bitget, the world's leading cryptocurrency exchange and Web3 company, has announced the listing of "Cat in a Dogs World" native tokens MEW, built on Solana ecosystem. The MEW tokens are listed on Spot corridor under innovation zone for memecoins. With the rise of memecoins, Solana projects have been gaining traction for their unique positioning. MEW stands out in the Solana ecosystem as a humour-driven project standing up in a world full of dog-themed memecoins. This token playfully asserts the emergence of a "cat season" in crypto, bringing back hype for feline-centric tokens. Being one of the leading memcoins on Solana, MEW captivates a shift in the crypto narrative on switching to cat-themed tokens, creating an increase in market movement for similar concept-based tokens. The listing of MEW comes with a promotional campaign running from April 3 to April 10, 2024. This campaign features a deposit rebate offering a 10% return, a trading competition based on transaction volumes, and a giveaway in MEW tokens. Participants are encouraged to engage with Bitget and MEW on social media, trade actively, and take advantage of these unique opportunities to win MEW rewards, enhancing their trading experience on the platform. At a chance to win MEW tokens, users can visit here. Bitget lists high potential tokens in its innovation zone to provide improved accessibility to emerging DeFi ecosystems. The inclusion of MEW in Bitget's spot helps users engage in the initial launch phases of the trending low-cap tokens. Bitget has consistently expanded its market share in both spot and derivatives trading among centralized exchanges. With a focus on providing users with opportunities to invest in popular and valuable projects, the platfrom is now one of the top 10 crypto spot trading platforms with over 700 coins and 800 pairs, including BTC, ETH, SOL and more. In 2023 alone, the platform added over 350 new listings, further diversifying investment options for users. Meanwhile, Bitget Wallet supports over 100 mainnets and 250,000+ tokens. Its on-chain trading function Bitget Swap enables cross-chain trading between nearly 30 mainnets. For more information about MEW tokens, users can visit. About Bitget Established in 2018, Bitget is the world's leading cryptocurrency exchange and Web3 company. Serving over 25 million users in 100+ countries and regions, the Bitget exchange is committed to helping users trade smarter with its pioneering copy trading feature and other trading solutions. Formerly known as BitKeep, Bitget Wallet is a world-class multi-chain crypto wallet that offers an array of comprehensive Web3 solutions and features including wallet functionality, swap, NFT Marketplace, DApp browser, and more. Bitget inspires individuals to embrace crypto through collaborations with credible partners, including legendary Argentinian footballer Lionel Messi and official eSports events organizer PGL. For more information, visit: Website | Twitter | Telegram | LinkedIn | Discord | Bitget Wallet Contact Details Bitget Simran A media@bitget.com Company Website https://www.bitget.com/

April 05, 2024 09:25 AM Eastern Daylight Time

Image
Article thumbnail News Release

The $7 Billion CBD Market in 2023 is Focused on Significant Growth in Personal Care

BYND Cannasoft Enterprises

ASHKELON, Israel and VANCOUVER, British Columbia – TheNewswire – (April 05, 2024) - BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (“BYND Cannasoft” or the “Company”) to utilize the "Razor-and-Blade" model * for its EZ-G device. * https://www.fool.com/investing/2017/01/13/razor-and-blade-model-what-is-it-what-companies-ha.aspx Disposable Capsules The business model built for the EZ - G device is based on the purchase of the device and the repurchase of various types of oil capsules.   In this way, the Company intends to maximize revenue while turning its customers into repeat purchasers of the variety of oils that the Company will offer. The Company is in advanced stages of product characterization of the first series of oil capsules, some of which will be based on CBD. This is done in partnership with Foria ®, a U.S based manufacturer of high-quality female wellness CBD oils. Growth in use of CBD for personal care The CBD market is expected to grow to $36 billion within a decade * due to a sharp increase in demand of oils for personal care, with the oil's properties evident in various fields. The Company seeks to harness the virtues of CBD combined with the rising demand for personal care and, through the EZ-G device, to integrate the oils into the user experience. The Company works together with Foria to produce a series of oils that will be specially adapted for women for both pleasure as well as therapy and are expected to create a "long-term contract" between the users and the Company for the regular repurchase of the oil's capsules. Initially, the Company will use two types of oils without CBD and two types based on CBD, which can be purchased in capsules together or separately with the EZ-G device immediately after it is released to the market.     * https://finance.yahoo.com/news/cannabidiol-market-soars-usd-36-075200774.html   CBD Skin Care Market The CBD skin care market is growing sharply year over year and by 2023 has reached $3 billion with estimates to reach $32 billion within a decade *. The Company plans to penetrate this field through new concept devices that have entered development and that through CBD oil capsules can provide facial and scalp care benefits. Smart cosmetic face device, utilizing smart release technology alongside interchangeable CBD serum capsules. This innovation allows users to seamlessly transition between treatments, catering to a variety of skin needs. In the hair wellness arena, the Company's proprietary technology has given rise to an innovative hair growth brush, designed to optimize hair treatment. By combining LED light therapy, gentle vibrations, and essential CBD capsules, this brush aims to foster an ideal environment for hair growth, ensuring comprehensive care for every hair follicle.   *https://www.futuremarketinsights.com/reports/cbd-skin-care-market About BYND Cannasoft Enterprises Inc. BYND Cannasoft Enterprises is an Israeli-based integrated software company. BYND Cannasoft owns and markets "Benefit CRM", a proprietary customer relationship management (CRM) software product enabling small and medium‐sized businesses to optimize their day‐to‐day business activities such as sales management, personnel management, marketing, call center activities, and asset management.  BYND Cannasoft owns the patent-pending intellectual property for the EZ-G device. This therapeutic device uses proprietary software to regulate the flow of low concentrations of CBD oil, hemp seed oil, and other natural oils into the soft tissues of the female reproductive system to potentially treat a wide variety of women's health issues. The EZ-G device includes technological advancements as a sex toy with a more realistic experience and the prototype utilizes sensors to determine what enhances the users' pleasure. The user can control the device through a Bluetooth app installed on a smartphone or other portable device. The data will be transmitted and received from the device to and from the secure cloud using artificial intelligence (AI). The data is combined with other antonymic user preferences to improve its operation by increasing sexual satisfaction. Commercialization of the EZ-G device is subject to receipt of regulatory approvals. The devices described in this news release are concept devices that are in the first stage of development and will be subject to testing, experiments and regulatory approvals and therefore there is no certainty that they will eventually be marketed. For further information please refer to information available on the Company’s website: www.cannasoft-crm.com, and on SEDAR+: www.sedarplus.ca. Gabi Kabazo Chief Financial Officer Tel: (604) 833-6820 e‐mail:  ir@cannasoft-crm.com   Cautionary Note Regarding Forward-Looking Statements This press release includes certain statements that may be deemed “forward-looking statements” within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended and under Canadian securities laws. When used in this press release, the words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions are intended to identify forward‐looking statements. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual events or developments may differ materially from those in forward-looking statements. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause the Company’s actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Such statements reflect the Company's current views with respect to future events and are subject to such risks and uncertainties. Many factors could cause actual results to differ materially from the statements made, including future financial performance, unanticipated regulatory requests and delays, final patents approval, and those factors discussed in filings made by the company with the Canadian securities regulatory authorities, including (without limitation) in the company's management's discussion and analysis for the year ended December 31, 2023 and annual information form dated April 2, 2024, which are available under the company's profile at www.sedarplus.ca, and in the Company’s Annual Report on Form 20-F for the year then ended that was filed with the U.S. Securities and Exchange Commission on April 3, 2024. Should one or more of these factors occur, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, or expected. We do not intend and do not assume any obligation to update these forward‐looking statements, except as required by law. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. Shareholders are cautioned not to put undue reliance on such forward‐looking statements.

April 05, 2024 09:00 AM Eastern Daylight Time

Article thumbnail News Release

Automated Trading On The Rise As Companies Push Workers Back To The Office

EdgeClear

By Austin DeNoce, Benzinga As the world gradually moves on from the shadow of the pandemic, the corporate drumbeat calling employees back to the office is growing louder. Leading the charge are companies like Goldman Sachs (NYSE: GS) and Alphabet Inc. (NASDAQ: GOOGL), alongside an overwhelming 90% of company leaders who are determined to enforce return-to-office policies by the end of 2024. This shift, driven by concerns about productivity, collaboration and the intangible benefits of in-office work, signals a significant change for employees and traders who've grown accustomed to the flexibility of remote work. Solutions For Traders Returning To The Office If you’re a trader heading back to the office, there are still ways to stay active in the markets without compromising your professional responsibilities. Automated trading strategies are a possible solution, as they enable traders to engage with the markets throughout the day, despite limited screen time. Swing trading also stands out as a time-friendly strategy for traders with busy daily schedules, allowing them to utilize after-hours planning to set market-on-open and market-on-close orders that can be filled while they’re away at work. Both automated and swing trading strategies can accommodate the demands of a full-time job. Since futures trading involves the risk of loss, it should be noted automation can help minimize the emotional pitfalls of trading by leveraging algorithms. Such systems have fully automated alerts and executions, which dramatically reduces the need for market surveillance and enables a more balanced approach to work and trading. Markets won’t adjust to your work schedule, so automation is one way to manage risk and stay on top of trades while your attention is focused on work. How EdgeClear Is Empowering Traders Against the backdrop of return-to-office policies, EdgeClear has positioned itself as a valuable resource for traders seeking to balance their time constraints with their thirst for markets. As a futures broker with an advanced suite of services, EdgeClear offers automated quantitative programs like EdgeQX and EdgeQX-R specifically tailored for intraday futures trading. These programs are designed with the modern trader in mind, incorporating machine learning and diversified signals to facilitate emotion-free trading across E-mini S&P 500 and Micro E-mini S&P 500 contracts. With EdgeClear, traders can enjoy transparency, flexibility in subscription management and access to sophisticated trading algorithms. This blend of features ensures that traders can maintain an active presence in the market, regardless of their return-to-office commitments. Ultimately, these automated services highlight EdgeClear's commitment to aligning trading strategies with the evolving work arrangements of traders. Navigating New Normals The transition back to office work represents a significant shift in the corporate landscape, challenging employees and traders to find new ways of balancing professional commitments with personal and trading activities. However, automated trading strategies, supported by platforms like EdgeClear, offer a viable option for traders to remain active in the markets while adapting to the demands of in-office work schedules. By embracing these tools and strategies, traders can navigate the post-pandemic return-to-office with confidence and without sacrificing their trading. The ability to adapt and leverage technology is itself a powerful edge in trading, making automated services a worthwhile consideration regardless of a trader’s time constraints. However, if you are busy with work, rest assured we live in a world filled with innovative solutions and brokers like EdgeClear allow traders to maintain their presence in markets no matter what occupies their time throughout the day. Featured photo by Maxim Hopman on Unsplash. A forward-thinking futures broker. Led by industry experts who understand the complexities of trading, Edge Clear combines the best of technology, service and risk control. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Max Timmins max@edgeclear.com

April 05, 2024 08:45 AM Eastern Daylight Time

Image
Article thumbnail News Release

Unlocking the Power of Immunotherapy: Elicio Therapeutics’ (NASDAQ: ELTX) Novel AMP Platform

Benzinga

By Jeremy Golden, Benzinga Approximately two million people were diagnosed with cancer in the U.S. in 2023, with breast, prostate, lung and bronchus cancers among the most common. An estimated 609,820 people died of cancer last year. The most common treatments are surgery, chemotherapy and radiation, though other options include targeted therapy as well as laser and hormonal therapies. Another treatment option is immunotherapy, which is designed to utilize the immune system to fight cancer. Immune responses are orchestrated by key immune cells in the lymph nodes, but for many therapies, getting to these critical sites is far from certain. Small molecule-based immunomodulators easily pass through the blood vessel walls at the injection site. As a result, they are rapidly flushed away into the systemic circulation, limiting access to the lymph nodes. Often, this results in a failure to realize the full potential of the immune response. Worse yet, it can lead to the development of dangerous toxicities at other sites in the body. Elicio Therapeutics’ Novel Approach Founded in 2011, Elicio Therapeutics, Inc. (NASDAQ: ELTX) is developing treatment options aimed at significantly improving the quality of life for cancer patients through the utilization of precision vaccines, immunomodulators and cell-based therapies to potentially assemble cancer-killing immune responses against solid tumors. The company is optimistic about the potential of lymph node-targeting made possible by applying the natural trafficking pathways of larger molecules. This approach differentiates Elicio from its competitors and could be highly promising for enhancing anti-tumor immune responses and improving therapeutic efficacy. Developed at the Massachusetts Institute of Technology (MIT), the company’s proprietary Amphiphile or “AMP” platform, which combines expertise in materials science and immunology, is being used to develop novel immunotherapies, including cell therapy activators, immunomodulators, adjuvants and vaccines for an array of aggressive cancers and infectious diseases. Here’s how it works: The AMP platform is designed to deliver therapeutic payloads directly to critical immune cells in the lymph nodes, enhancing the cancer-fighting mechanisms of the immune system. By delivering cancer immunotherapies to the center of the immune response, this approach is intended to optimize the natural ability of the lymph nodes to educate, activate and amplify cancer-specific T cells. Engineered to coordinate immunity in these uniquely potent sites, the AMP platform was built to amplify the magnitude, potency, quality and durability of the immune response to drive antitumor activity. At the injection site, the platform prevents detrimental payload delivery to systemic circulation, instead guiding the payloads into the lymphatics to promote lymph node delivery. Additionally, it preserves the structural integrity and activity of payloads by preventing any degradation prior to uptake by lymph node resident immune cells. Upon reaching the lymph nodes, the platform optimizes retention and directs the delivery of payloads to key immune cells responsible for the coordination of immune responses, specifically the activation and amplification of cancer-specific immune cells in lymph nodes. Overall, Elicio Therapeutics anticipates that the AMP platform could potentially provide a better quality of life to patients during treatment. The strategy is set apart from other treatments by its ability to activate immune mechanisms directly in the lymph nodes. Enhanced T cell infiltration into tumors, improved T cell expansion and persistence, potent anti-tumor T cell function and wide breadth of response are key attributes with the potential to improve efficacy and reduce the risk of resistance to therapy. Moving forward, Elicio Therapeutics is committed to developing its lymph node-targeting approach for deployment across a range of vaccines, immunomodulators and adjuvants — training the immune system to put the best cells forward to fight a broad spectrum of cancers. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

April 05, 2024 08:15 AM Eastern Daylight Time

Image
Article thumbnail News Release

FeganScott Announces Lawsuit Against Hyundai and Kia Over Alleged Defect in Certain Hybrid-Electric Vehicles that Poses Serious Safety Risks

FeganScott

FeganScott announces it has filed a class action lawsuit on behalf of Hyundai and Kia vehicle owners and lessees, claiming the automobile manufacturers sold thousands of hybrid-electric vehicles containing a defect that poses serious safety risks to drivers and passengers. The lawsuit revolves around a defect in the engine clutch actuator (ECA), sometimes called the hydraulic clutch actuator. The vehicles named in the suit include 2017-2022 Kia Niro Hybrid, 2018-2022 Kia Niro Plug-In Hybrid, and 2017-2022 Hyundai Ioniq Hybrid vehicles. According to the complaint filed in the U.S. District Court for the Central District of California, the defect allows fluid to leak into the engine clutch actuator, which can cause the car to stall and, in some reported instances, start a vehicle fire. In July 2023, Kia issued a safety recall for certain Niro Hybrid vehicles due to the alleged ECA defect. However, the lawsuit states that the recall failed to fix the root cause of the defect, and that it does not prevent the risk of stalled vehicles. The suit also notes that Hyundai installed the same ECA component in its Hyundai Ioniq Hybrid vehicles and has not issued a safety recall. “Hyundai and Kia have a long history of failing to issue timely and complete fixes for known defects in their vehicles, and this latest defect with the engine clutch actuator in certain hybrid-electric models is no different,” said FeganScott attorney Jonathan Lindenfeld. “Our firm has devoted significant time and resources to ensure that the largest automobile manufacturers in the world live up to their responsibilities. Consumers who spend tens of thousands of dollars for their vehicles deserve products that are safe and reliable.” Drivers of the affected vehicles are encouraged to send their contact information to autosafety@feganscott.com to learn more about their rights. # # # Case No. 8:24-cv-00731 About FeganScott FeganScott is a national class action law firm dedicated to helping victims of consumer fraud, sexual abuse, and discrimination. The firm is championed by acclaimed veteran class action attorneys who have successfully recovered $1 billion for victims nationwide. FeganScott is committed to pursuing successful outcomes with integrity and excellence while holding the responsible parties accountable. Contact Details Mark Firmani +1 206-466-2700 feganscottpr@firmani.com Company Website https://feganscott.com

April 05, 2024 08:00 AM Eastern Daylight Time

Article thumbnail News Release

Platinum Learning Nursing CE Announces Continuing Education Programs for Healthcare Professionals

Rev Up Marketers

Platinum Learning Nursing CE, a provider of continuing education (CE) for healthcare professionals, has announced a new lineup of programs designed to meet the educational needs of registered nurses (RNs), licensed vocational nurses (LVNs), licensed psychiatric technicians (LPTs), and advanced practice registered nurses (APRNs). These programs cover a wide range of topics essential for maintaining competency and staying up-to-date with the latest advancements in healthcare. Focus on Registered Nurses (RNs) Registered nurses play a vital role in the healthcare system, providing care to patients in various settings. To maintain their licensure, RNs in most states, including California, are required to complete a certain number of CE credits every renewal period as mandated by the California Board of Registered Nursing (BRN). When searching for RN license renewal CE providers, Platinum Learning Nursing CE stands out with its comprehensive curriculum and engaging learning formats. Their CE programs for RNs address a variety of relevant subjects, including: Medical-Surgical Nursing Critical Care Nursing Pediatric Nursing Geriatric Nursing Mental Health Nursing Leadership and Management Legal and Ethical Issues in Nursing The programs are designed to be informative and engaging, featuring interactive modules, case studies, and self-assessments to reinforce learning. Addressing LVN License Renewal in California Licensed vocational nurses (LVNs) are an essential part of the healthcare team, working under the supervision of RNs and physicians to provide direct patient care. In California, LVNs are mandated to complete 30 CE hours for each license renewal cycle. The company offers a comprehensive selection of CE programs specifically tailored to the needs of LVNs in California, encompassing topics directly relevant to LVN license renewal in California, such as: Basic Nursing Skills Medication Administration Wound Care Infection Control Communication and Collaboration Documentation and Reporting These programs are developed to ensure LVNs meet the California Board of Vocational Nursing and Psychiatric Technicians (BVNPT) requirements for license renewal. Continuing Education Opportunities for Other Healthcare Professionals The company also caters to the educational needs of licensed psychiatric technicians (LPTs) and advanced practice registered nurses (APRNs). LPT programs address mental health assessment, crisis intervention, and psychopharmacology, while APRN programs delve into areas like primary care, family practice, and acute care. Conclusion Platinum Learning Nursing CE's commitment to providing high-quality, accessible CE programs empowers healthcare professionals across various disciplines to enhance their knowledge, skills, and abilities. This focus on continuing education fosters better patient care, improved healthcare outcomes, and a more competent healthcare workforce. For any press-related queries or additional details, please mail to support@platinumlearningce.org or visit https://www.platinumlearningce.org/. About Platinum Learning Nursing CE Platinum Learning Nursing CE is a dedicated provider of continuing education programs for healthcare professionals, including registered nurses, licensed vocational nurses, licensed psychiatric technicians, and advanced practice registered nurses. Their mission is to empower nurses and other healthcare providers with the knowledge and skills necessary to deliver exceptional patient care. Their programs are developed by industry experts and adhere to the latest guidelines and regulations set forth by regulatory bodies. Contact Details Platinum Learning Nursing CE Irine Achuamang +1 424-347-0362 info@platinumlearningce.org Company Website https://www.platinumlearningce.org/

April 04, 2024 05:31 PM Eastern Daylight Time

Image
1 ... 288289290291292 ... 3753